fbpx
Size of letters 1x
Site color
Image
Additionally
Line height
Letter spacing
Font
Embedded items (videos, maps, etc.)
 

Sona-Pharm Group Celebrates 20 Years of Success and Commitment to Partnership!

06/ 06/ 2024
  Sona-Pharm, a group of distribution companies is proud to announce its 20th anniversary. Since its foundation at the end of 2003, Sona-Pharm Group has become a distributor of medicines from the worlds leading manufacturers in the fields of reproductive health, oncology, neurology, psychiatry, ophthalmology, gastroenterology, and angiology. Over the years, Sona-Pharm Group has grown from a small distributor to a significant and dynamically growing player in the healthcare industry. Through unwavering dedication and a relentless pursuit of excellence, the company can be proud of its achievements: we established a partnership with leading international pharmaceutical companies such as Merck KGgA, Lundbeck, Alfasigma, Ursapharm, Pharmaten, Magis/Aesculapius Farmaceutici, BIOCODEX, VISU Pharma; 4 trading companies have been created: “Sona-Pharm” (Ukraine), “Sona-Pharm Kazakhstan”, “Sona-Pharmexim” (Ukraine) and “Sona-Pharmexim” (Kazakhstan) that supply products and operate in eight countries in Europe and Central Asia; more than 150 employees provide the necessary support throughout the lifecycle of medicines and medical devices, including but not limited to regulatory activities, market access, pharmacovigilance and quality assurance, logistics, medical and promotional activities in accordance with international standards; we launched more than 60 products. By developing cooperation in two segments of the pharmaceutical business – hospital and retail, Sona-Pharm Group creates a stable foundation for further growth. The hospital line is represented by Sona-Pharm company itself, which is a partner of Merck KGgA and Lundbeck, and over the past six years the company has demonstrated a two-fold increase in turnover. In the field of reproductive medicine, Sona-Pharm company became a reliable partner of clinics specializing in assisted reproductive technologies, which advance the development of practical and scientific potential of doctors. The companys scientific and educational support of medical communities contributes to the development of this field as a whole, which ultimately facilitates the access of patients to reproductive technologies in a number of countries, including Ukraine, Kazakhstan and countries of Central Asia. In particular, in Uzbekistan, such scientific support became the impetus for the creation of a legislative framework in the field of reproductive medicine and the emergence of a new direction in medicine in this country, which opened the possibility of using reproductive technologies for doctors and gave hope for long-awaited parenthood to patients. Being a group member, Sona-Pharmexim company founded at the end of 2015 is developing cooperation in the retail line and with such manufacturers as Alfasigma, Ursapharm, Pharmaten, Magis/Aesculapius Farmaceutici, BIOCODEX, VISU Pharma in the fields of gastroenterology, cardio- and angioprotection, and ophthalmology. Over the past 5 years, Sona-Pharmexim has improved its market position in Ukraine from 113th place in 2018 to 73rd place in 2023, and doubled its turnover in Ukraine and Kazakhstan, confidently occupying leadership positions in the target markets. Over 20 years of operation, Sona-Pharm Group has demonstrated the ability to adapt and grow in various healthcare systems despite instability and multifaceted changes in the modern world and steadily continues to fulfill its commitments to patients and partners. “2024 is a very special year for our company, and it’s time to express our gratitude to all our partners and dedicated employees, who have been the cornerstone of our success, said Ostap Kupnovytskyi, Co-Founder and General Manager of Sona-Pharm. Most employees are working for Sona-Pharm for many years, and we value that much. We are incredibly grateful to all our partners for their trust and maintenance of long-term contracts, who have been integral to our success throughout our 20-year journey. This important milestone signifies both years of hard work and great potential that lies ahead as we continue to focus on unmet patient needs.” Sona-Pharm Group is proud of the cooperation with our international and local partners, their great contribution to research and development in dedicated fields, consistent enhancement of medical care through continuous education, technical re-equipment, and application of advanced technologies and treatment methods. “Sona-Pharm is a friendly team of experienced professionals, united by a common goal — improving the lives of patients. Our daily work is aimed at expanding patients’ access to high-quality medicines, and providing doctors with cutting-edge solutions,” indicated Nataliia Korniienko, Co-Founder and Commercial Director of Sona-Pharm. “We are proud to help people in many countries to treat serious illnesses, improve their life quality, and give them the happiness of being parents. Together with our partners, we can leverage the worlds best practices to improve patient care.” Looking to the future, Sona-Pharm Group aims to further enhance its current business, explore new market opportunities, and continue to address patient’s needs. In the five-year perspective, our ambitions include achieving double-digit business growth, expanding the product portfolio and geography of our presence, as well as continuous improvement of the work standards.

Sona-Pharm, a group of distribution companies is proud to announce its 20th anniversary. Since its foundation at the end of 2003, Sona-Pharm Group has become a distributor of medicines from the world’s leading manufacturers in the fields of reproductive health, oncology, neurology, psychiatry, ophthalmology, gastroenterology, and angiology.

Over the years, Sona-Pharm Group has grown from a small distributor to a significant and dynamically growing player in the healthcare industry. Through unwavering dedication and a relentless pursuit of excellence, the company can be proud of its achievements:

  • we established a partnership with leading international pharmaceutical companies such as Merck KGgA, Lundbeck, Alfasigma, Ursapharm, Pharmaten, Magis/Aesculapius Farmaceutici, BIOCODEX, VISU Pharma;
  • 4 trading companies have been created: “Sona-Pharm” (Ukraine), “Sona-Pharm Kazakhstan”, “Sona-Pharmexim” (Ukraine) and “Sona-Pharmexim” (Kazakhstan) that supply products and operate in eight countries in Europe and Central Asia;
  • more than 150 employees provide the necessary support throughout the lifecycle of medicines and medical devices, including but not limited to regulatory activities, market access, pharmacovigilance and quality assurance, logistics, medical and promotional activities in accordance with international standards;
  • we launched more than 60 products.

By developing cooperation in two segments of the pharmaceutical business – hospital and retail, Sona-Pharm Group creates a stable foundation for further growth.

The hospital line is represented by Sona-Pharm company itself, which is a partner of Merck KGgA and Lundbeck, and over the past six years the company has demonstrated a two-fold increase in turnover.

In the field of reproductive medicine, Sona-Pharm company became a reliable partner of clinics specializing in assisted reproductive technologies, which advance the development of practical and scientific potential of doctors. The company’s scientific and educational support of medical communities contributes to the development of this field as a whole, which ultimately facilitates the access of patients to reproductive technologies in a number of countries, including Ukraine, Kazakhstan and countries of Central Asia. In particular, in Uzbekistan, such scientific support became the impetus for the creation of a legislative framework in the field of reproductive medicine and the emergence of a new direction in medicine in this country, which opened the possibility of using reproductive technologies for doctors and gave hope for long-awaited parenthood to patients.

Being a group member, Sona-Pharmexim company founded at the end of 2015 is developing cooperation in the retail line and with such manufacturers as Alfasigma, Ursapharm, Pharmaten, Magis/Aesculapius Farmaceutici, BIOCODEX, VISU Pharma in the fields of gastroenterology, cardio- and angioprotection, and ophthalmology. Over the past 5 years, Sona-Pharmexim has improved its market position in Ukraine from 113th place in 2018 to 73rd place in 2023, and doubled its turnover in Ukraine and Kazakhstan, confidently occupying leadership positions in the target markets.

Over 20 years of operation, Sona-Pharm Group has demonstrated the ability to adapt and grow in various healthcare systems despite instability and multifaceted changes in the modern world and steadily continues to fulfill its commitments to patients and partners.

“2024 is a very special year for our company, and it’s time to express our gratitude to all our partners and dedicated employees, who have been the cornerstone of our success,” said Ostap Kupnovytskyi, Co-Founder and General Manager of Sona-Pharm. “Most employees are working for Sona-Pharm for many years, and we value that much. We are incredibly grateful to all our partners for their trust and maintenance of long-term contracts, who have been integral to our success throughout our 20-year journey. This important milestone signifies both years of hard work and great potential that lies ahead as we continue to focus on unmet patient needs.”

Sona-Pharm Group is proud of the cooperation with our international and local partners, their great contribution to research and development in dedicated fields, consistent enhancement of medical care through continuous education, technical re-equipment, and application of advanced technologies and treatment methods.

“Sona-Pharm is a friendly team of experienced professionals, united by a common goal — improving the lives of patients. Our daily work is aimed at expanding patients’ access to high-quality medicines, and providing doctors with cutting-edge solutions,” indicated Nataliia Korniienko, Co-Founder and Commercial Director of Sona-Pharm. “We are proud to help people in many countries to treat serious illnesses, improve their life quality, and give them the happiness of being parents. Together with our partners, we can leverage the world’s best practices to improve patient care.”

Looking to the future, Sona-Pharm Group aims to further enhance its current business, explore new market opportunities, and continue to address patient’s needs.

In the five-year perspective, our ambitions include achieving double-digit business growth, expanding the product portfolio and geography of our presence, as well as continuous improvement of the work standards.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Start
in the Telegram bot
Read articles. Share in social networks

Spelling error report

The following text will be sent to our editors: